Evidence map›Paper›PMID 25928510›Full record

ArticleInternational braz j urol : official journal of the Brazilian Society of Urology

Short-term prophylaxis with ciprofloxacin in extended 16-core prostate biopsy.

Renato Caretta Chambó, Fabio Hissachi Tsuji, Hamilton Akihissa Yamamoto, Carlos Marcio Nobrega de Jesus

Open access · diamondAbstract readEvaluation Study
In one paragraph

Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Renato Caretta ChambóBotucatu Medical School, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
Fabio Hissachi TsujiBotucatu Medical School, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
Hamilton Akihissa YamamotoBotucatu Medical School, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
Carlos Marcio Nobrega de JesusBotucatu Medical School, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
Universidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the safety, efficacy and possible complications of 16-core transrectal prostate biopsies using two doses of ciprofloxacin for prophylaxis of infectious complications. MATERIALS AND

methodsSixteen-core prostate biopsies were performed on a number of patients with different signs of potential prostate cancer. Complications were assessed both during the procedure and one week later. After the procedure, urine samples were collected for culture. The rate of post-biopsy complications, hospital visits and hospitalizations were also analyzed. Ciprofloxacin (500 mg) was administered two hours before, and eight hours after the procedure.

resultsThe overall rate of post-biopsy complications was 87.32%, being 5.4% of those considered major complications due to hemorrhage, or to urinary retention. Eight patients required hospital treatment post-biopsy. Fever occurred in just one patient (0.29%). There was no incidence of orchitis, epididymitis, prostatitis, septicemia, hospitalization, or death. The urine culture showed positive results in five patients (2.15%).

conclusionOne-day prophylaxis with ciprofloxacin proved to be safe and effective in the prevention of infectious complications following 16-core prostate biopsies.

Indexed as

Anti-Bacterial AgentsAntibiotic ProphylaxisCiprofloxacinHospitalizationHumansImage-Guided BiopsyMalePostoperative ComplicationsProspective StudiesProstateProstatic NeoplasmsReproducibility of ResultsRisk FactorsTime FactorsTreatment OutcomeUrinary Tract InfectionsAnti-Bacterial AgentsCiprofloxacin

Identifiers

PMID25928510
PMCPMC4752056
OpenAlexW2112411518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.